Physician profile
Mark Brown
NPI 1093767550
$1,950.10
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2020: $167 · 2022: $174 · 2023: $796 · 2024: $683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,479.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $392.93 | 2019-2024 | Arikayce |
| Paratek Pharmaceuticals, INC. | $363.77 | 2020-2024 | Nuzyra |
| Viiv Healthcare Company | $305.18 | 2022-2024 | Dovato |
| Gilead Sciences, INC. | $239.30 | 2023-2024 | |
| Angiodynamics, INC. | $173.64 | 2019-2023 | Angiovac |
| Abbvie INC. | $74.44 | 2023-2024 | Avycaz, Dalvance, Teflaro |
| Merck Sharp & Dohme LLC | $66.55 | 2019-2024 | Recarbrio, Zerbaxa, Dificid |
| Shionogi INC | $58.73 | 2023 | Fetroja |
| La Jolla Pharmaceutical Company | $49.76 | 2024 | Xerava |
| Smith+Nephew, INC. | $36.74 | 2023 | Collagenase Santyl, Regranex, Grafix Pl |
| Takeda Pharmaceuticals U.S.A., INC. | $32.73 | 2024 | Cuvitru |
| Csl Behring | $32.10 | 2023 | Hizentra |
| Accelerate Diagnostics INC. | $23.03 | 2019 | |
| Aimmune Therapeutics, INC. | $23.00 | 2023 | |
| Janssen Biotech, INC. | $22.92 | 2023 | Symtuza |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $22.18 | 2023 | Vibativ |
| Astrazeneca Pharmaceuticals Lp | $19.81 | 2022 | |
| Glaxosmithkline, LLC. | $13.29 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.